Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
ChengDu ShengNuo Biotec Co.,Ltd. (688117.SS)
Chengdu, CN
ChengDu ShengNuo Biotec Co.,Ltd. focuses on the entire lifecycle of peptide pharmaceuticals, from initial research and development to manufacturing, and their subsequent domestic and international distribution. The company's product portfolio encompasses active polypeptide ingredients (APIs), solid dosage tablets, and a diverse range of injectable formats, including freeze-dried powders, small-volume solutions, pre-filled syringes, and specialized card-type injections. This enterprise was established in 2001 and conducts its operations from Chengdu, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.55% | -5.73% | -9.84% | -11.98% | -17.73% | -10.74% | +27.96% | +74.68% | +0.93% | +0.93% | +0.93% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2025-12 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+62.6% ★ Q1'26: +32.5% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+222.6% ★ Q1'26: +40.0% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+8.8% Q1'26: -21.9% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+25.4% ★ Q1'26: +33.7% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+14.1% ★ Q1'26: +21.8% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%-0.8% ★ Q1'26: +0.6% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×1.61× Q1'26: 1.50× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|
| Revenue |
435.02M
est: 434.00M (+0.2%)
|
456.07M
est: 530.00M (-13.9%)
|
741.34M
est: 724.00M (+2.4%)
|
976.00M
976.00M – 976.00M
+34.8% YoY
|
1.19B
1.19B – 1.19B
+21.8% YoY
|
| EBITDA |
116.85M
est: 105.99M (+10.2%)
|
107.12M
est: 136.03M (-21.3%)
|
221.62M
est: 185.82M (+19.3%)
|
250.50M
250.50M – 250.50M
+34.8% YoY
|
305.17M
305.17M – 305.17M
+21.8% YoY
|
| EBIT |
89.20M
est: 80.04M (+11.4%)
|
73.52M
est: 105.41M (-30.3%)
|
188.03M
est: 143.99M (+30.6%)
|
194.11M
194.11M – 194.11M
+34.8% YoY
|
236.47M
236.47M – 236.47M
+21.8% YoY
|
| Net Income |
70.34M
est: 51.16M (+37.5%)
|
50.02M
est: 102.65M (-51.3%)
|
157.92M
est: 181.62M (-13.0%)
|
172.14M
172.14M – 172.14M
-5.2% YoY
|
235.31M
235.31M – 235.31M
+36.7% YoY
|
| SGA |
161.01M
est: 156.42M (+2.9%)
|
127.76M
est: 176.37M (-27.6%)
|
89.96M
est: 240.92M (-62.7%)
|
324.78M
324.78M – 324.78M
+34.8% YoY
|
395.66M
395.66M – 395.66M
+21.8% YoY
|
| EPS |
0.45
est: 0.45 (+0.0%)
|
0.32
est: 0.65 (-50.8%)
|
1.00
est: 1.15 (-13.0%)
|
1.09
1.09 – 1.09
-5.2% YoY
|
1.49
1.49 – 1.49
+36.7% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-28 | B | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-27 | B | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-26 | B | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-25 | B | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-22 | B | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-21 | B | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-20 | B | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-19 | B | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-18 | B | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-15 | B | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-14 | B | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-13 | B | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-12 | B | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-11 | B | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-08 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-07 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-06 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-30 | B- | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-29 | B- | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-28 | B- | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Changliang Lu | Deputy General Manager | — | male |
| Li Wu | Chief Financial Officer, Deputy GM & Director | — | male |
| Xiaohai Yu | Deputy GM, Board Secretary & Director | — | male |
| Xiaoli Wang | Director and Deputy General Manager | — | female |
| Yang Shi | Accounting Supervisor | — | — |
| Yongjun Wen | Chairman & GM | — | male |
| Zhonggang Ma | Deputy General Manager | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 688117.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
